バージニアにおける卵巣がんの臨床試験
バージニア内の拠点で、卵巣がんに関する57件の研究が参加者を募集しています。
バージニア内の都市
公式研究テキスト（英語）
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Ballad Health Cancer Care - Bristol, Bristol
- University of Virginia Cancer Center, Charlottesville
- Inova Schar Cancer Institute, Fairfax
- 他5件
被験者募集中第2相
全年齢 · 全性別 · 2026/10/02更新 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Virginia Cancer Specialists, Fairfax
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Inova Schar Cancer Institute, Fairfax
- NEXT Virginia, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06270706A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- University of Virginia, Charlottesville
- NEXT Virginia, Fairfax
被験者募集中第1相
19歳以上 · 全性別 · 2026/10/01更新 · NCT06586957A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- Next Virginia /ID# 279684, Fairfax
被験者募集中第2相
18歳以上 · 女性 · 2026/10/01更新 · NCT07024784A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
- Next Virginia /ID# 278607, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07278336A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 04, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07814248First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- NEXT Virginia, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06799065A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0295 - Virginia Oncology Associates, Chesapeake
- Site 0322 - Inova Schar Cancer Institute, Fairfax
被験者募集中第2相
18歳以上 · 女性 · 2026/09/29更新 · NCT05128825A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- UVA Health University Hospital /ID# 275309, Charlottesville
- Inova Schar Cancer Institute - Fairfax - Innovation Park Drive /ID# 276456, Fairfax
- Virginia Oncology Associates- Norfolk (Brock) /ID# 275227, Norfolk
- 他1件
被験者募集中第2相
18歳以上 · 女性 · 2026/09/29更新 · NCT06890338Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Virginia Commonwealth University/ Massey Cancer Center, Richmond
被験者募集中観察研究
18歳以上 · 女性 · 2026/09/29更新 · NCT05051722Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05867251Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Virginia Commonwealth University, Richmond
被験者募集中第1/2相
18歳以上 · 女性 · 2026/09/25更新 · NCT03564340Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- NEXT Oncology Virginia, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06128551Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Virginia Cancer Specialists, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/21更新 · NCT05983432A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- NEXT Oncology, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07109726A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Virginia Cancer Specialists (VCS) ( Site 8012), Fairfax
- Virginia Oncology Associates (VOA) ( Site 8013), Norfolk
被験者募集中第3相
18歳以上 · 女性 · 2026/09/17更新 · NCT07318558A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Virginia Cancer Specialists, Fairfax
- Carilion Clinic, Roanoke
被験者募集中第2相
18歳〜99歳 · 女性 · 2026/09/15更新 · NCT07023627Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- University of Virginia Health System, Charlottesville
- Inova Schar Cancer Institute, Fairfax
被験者募集中第3相
18歳以上 · 女性 · 2026/09/15更新 · NCT07214779FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Inova Schar Cancer Institute, Fairfax
- Next Oncology Virginia, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT06303505Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Virginia Cancer Specialists, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06293898Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
- NEXT Oncology, Fairfax
被験者募集中第1相
18歳以上 · 女性 · 2026/09/03更新 · NCT07755436A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Virginia Cancer Specialists (VCS) ( Site 8011), Fairfax
被験者募集中第3相
18歳以上 · 女性 · 2026/09/03更新 · NCT06824467The Vanguard Study: Testing a New Way to Screen for Cancer
- Sentara Martha Jefferson Hospital, Charlottesville
- Inova Schar Cancer Institute, Fairfax
- Inova Fair Oaks Hospital, Fairfax
- 他5件
被験者募集中健康なボランティア歓迎
45歳〜75歳 · 全性別 · 2026/09/02更新 · NCT06995898Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- University of Virginia, Charlottesville
被験者募集中第1相
15歳以上 · 全性別 · 2026/08/25更新 · NCT06276491A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Inova Schar Cancer Institute, Falls Church
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/21更新 · NCT06774963Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Fairfax
被験者募集中第1/2相
18歳〜130歳 · 全性別 · 2026/08/21更新 · NCT05797168A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07182149A Study of PHST001 in Advanced Solid Tumors
- NEXT Oncology - Virginia, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/12更新 · NCT06840886A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- University of Virginia Cancer Center, Charlottesville
- Inova Schar Cancer Institute, Fairfax
- Inova Fair Oaks Hospital, Fairfax
- 他5件
被験者募集中
35歳〜50歳 · 女性 · 2026/08/07更新 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- University of Virginia Cancer Center, Charlottesville
- VCU Massey Comprehensive Cancer Center, Richmond
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/07更新 · NCT06580314A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/06更新 · NCT07749586Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
- NEXT Oncology - Virginia Cancer Specialists, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/05更新 · NCT07444814A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Virginia Cancer Specialists, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/05更新 · NCT06330064Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Virginia Cancer Specialists, Fairfax
- USOR Virginia Oncology Associates, Norfolk
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Virginia Cancer Specialists, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/30更新 · NCT04657068A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- University of Virginia Comprehensive Cancer Center, Charlottesville
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/07/28更新 · NCT06161025Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
- NEXT Virginia, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/22更新 · NCT07524322Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 522, Fairfax
- 300, Norfolk
被験者募集中第2相
18歳以上 · 女性 · 2026/07/16更新 · NCT06906341Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- University of Virginia, Richmond
被験者募集中第2相
18歳以上 · 女性 · 2026/07/14更新 · NCT04606914ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。